Register for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma.
Tune in for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma. As the complexity of cancer management continues to mount, clinicians frequently face difficult therapeutic decisions that mandate the input from colleagues and various specialties critical for optimizing patient care.
Hear experts provide their perspectives from urology, medical oncology, and radiation oncology on multiple cases:
We will be polling the audience live to interact with the experts on how they would treat.
Register at: https://primetime.bluejeans.com/a2m/register/bcgrjfbp?utm_source=social&utm_medium=post&utm_campaign=registration
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
FDA approves nivolumab plus cisplatin/gemcitabine in urothelial carcinoma
March 7th 2024The approval is based on data from the phase 3 CheckMate-901 trial, which demonstrated improved overall survival and progression-free survival with the nivolumab-combination therapy vs cisplatin/gemcitabine alone.
EV-302 data on EV/pembro in urothelial carcinoma published in NEJM
March 7th 2024Data showed that the combination of EV and pembrolizumab extended overall survival and progression-free survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.